Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Process-upgraded recombinant hepatitis B vaccine lot consistency study in healthy young adults
2004-005023-18Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2005
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of Hepatitis B vaccine in hepatitis B (HBV) (4 arms), sponsored by Merck & Co. Primary endpoints: Lot-to-lot consistency in seroprotection rate, Adequate seroprotection rate for combined upgraded lots and 1 more. Started Apr 2005; status: completed.
02
Drugs
Hepatitis B vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on 2004-005023-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005023-18.